TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03235778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
Study: NCT03828045

Intervention type: DRUG
Intervention: Apremilast
Description: Apremilast
Study: NCT01521195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal blood flow via ECMO machine
Description: Extracorporeal Membrane Oxygenation (ECMO) machine can provide complete support of heart and lung function.~Extracorporeal blood flow will be given at baseline rate, increased by 25% and decreased by 25%
Study: NCT01695109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: sc injections of 0.6 mg Liraglutide daily for three continuous days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl, 0.2 ml
Study: NCT00704795

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: 50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: 50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).

Intervention type: OTHER
Intervention: Isoglycemic iv glucose infusion
Description: The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.

Intervention type: OTHER
Intervention: Isoglycemic iv glucose infusion
Description: The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
Study: NCT00524758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ologen (oculusgen) collagen matrix
Description: Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC in Trabeculectomy
Description: MMC in Trabeculectomy
Study: NCT03363815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001
Study: NCT01837121

Intervention type: OTHER
Group type: OTHER
Intervention: the SMS reminder message
Description: the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.
Study: NCT02266888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab (Rituxan®)
Description: 2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
Study: NCT02859571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study: NCT01926457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of Prediabetes
Description: Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~* diabetes education~* blood glucose monitoring~* medications as needed per California Diabetes and Pregnancy established protocol~* growth ultrasounds~* antenatal testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of Prediabetes
Description: Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~* diabetes education~* blood glucose monitoring~* medications as needed per California Diabetes and Pregnancy established protocol~* growth ultrasounds~* antenatal testing
Study: NCT02132988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-822/OPT-821
Study: NCT03363815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Vitamin K

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib
Study: NCT03718286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
Study: NCT03834428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Intervention
Description: A text message will be sent once daily (between noon and 3p) to remind participants to ambulate at least 3 times each day while hospitalized.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICOUGH protocol
Description: Education will be provided about the ICOUGH protocol which includes: Incentive spirometry (a breathing device that expands the lungs), Coughing and deep breathing, Oral hygiene (for example using a toothbrush), Understanding (patient and family education), Getting out of bed at least three times daily, and Head-of-bed elevation to prevent choking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICOUGH protocol
Description: Education will be provided about the ICOUGH protocol which includes: Incentive spirometry (a breathing device that expands the lungs), Coughing and deep breathing, Oral hygiene (for example using a toothbrush), Understanding (patient and family education), Getting out of bed at least three times daily, and Head-of-bed elevation to prevent choking.
Study: NCT01808300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg, Thioctic acid 600mg
Description: * A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg, Thioctic acid 600mg
Description: * A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg, Thioctic acid 600mg
Description: * A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg, Thioctic acid 600mg
Description: * A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg, Thioctic acid 600mg
Description: * A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B
Study: NCT04126941

Intervention type: OTHER
Intervention: Serum calcium concentrations results
Description: To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
Study: NCT00972062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bach's Rescue Remedy Cream
Description: 0.5 ml of cream applied to skin site reactions as needed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream 0.5 ml two times a day as needed
Study: NCT03841604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide Methanesulfonate
Description: 50 mg, 100 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Safinamide methanesulfonate matching placebo
Description: 50 mg, 100 mg
Study: NCT01635439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propess
Description: The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostin E2
Description: 3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.
Study: NCT03247946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: upright head position
Description: Bottle feeding of infants with their head in upward and not supine head position
Study: NCT03689621

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation (tVNS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Study: NCT03868657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin is solely used to cause a known and for the drug well documented effect, namely blockade of the Kv11.1 channel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03153943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIP Mobile e-Monitoring support
Description: 3-month community-based extended-rehabilitation e-Monitoring and Coaching support program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workbook support
Description: Printed material support
Study: NCT01129856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate ophthalmic solution
Description: Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate ophthalmic solution
Description: Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium citrate buffer solution
Description: Sodium citrate buffer solution 100 mM
Study: NCT01337960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated Robot Training (SRT)
Description: Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Locomotor-based Training (TMR)
Description: Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Only (TMO)
Description: Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
Study: NCT00384670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue Vaccine Formulation 17
Description: Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed Japanese Encephalitis (JE) Vaccine
Description: Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
Study: NCT03452657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Participants in arm Ranibizumab will receive ranibizumab injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No drug
Description: Participants in arm Sham-injection will receive sham injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year.
Study: NCT02809482

Intervention type: OTHER
Group type: OTHER
Intervention: Eucaloric feeding
Description: 3 days of a diet designed to maintain energy balance

Intervention type: OTHER
Group type: OTHER
Intervention: Overfeeding
Description: 3 days of a diet designed to induce a 40% positive energy balance
Study: NCT03040336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The 6-week long prehabilitation intervention will include (1) strength and balance training; (2) inspiratory muscle training; and (3) nutritional coaching and supplementation.
Study: NCT01747876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 is a small molecule inhibitor of CDK4/6.
Study: NCT04380285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom heel pads and modified soft molded orthotics

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom hard orthotic
Study: NCT04226755

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: 1 gram tid (with every meal)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium chloride
Description: 1 gram tid (with every meal)
Study: NCT06223984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pulse steroid and nanogam
Description: patients received pulse steroid and ivig treatments in addition to standard treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pulse steroid and nanogam
Description: patients received pulse steroid and ivig treatments in addition to standard treatment.
Study: NCT00779155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Resonator
Description: active magnetic field therapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The Resonator control
Description: inactive magnetic field therapy with placebo fields
Study: NCT03387085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Aldoxorubicin hydrochloride

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-MUC1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK for Infusion
Description: NK-92 \[CD16.158V, ER IL-2\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cis-diamminedichloroplatinum(II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study: NCT01885741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPBS
Study: NCT01737437

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: group C
Description: 0.9% normal saline was applied to trachea and laryngoscope blade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group L
Description: 10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group V
Description: 0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group LV
Description: 10% Lidocaine was applied on laryngoscope blade and trachea.
Study: NCT03762317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: clonidine will be given at 12 mcg/kg/d to the experimental arm in addition to oral morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with volume similar to clonidine at 12 mcg/kg/d will be given to this arm in addition to oral morphine
Study: NCT00735436

Intervention type: DRUG
Group type: OTHER
Intervention: Gliadel/Avastin/CPT-11